Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Rare Cancer, Education

    Rare Tumor Case Highlights Importance of Accurate Diagnosis in Sarcoma Care

    April 2, 2026 ayushis Comments Off on Rare Tumor Case Highlights Importance of Accurate Diagnosis in Sarcoma Care
    A doctor in a white coat with a stethoscope holds a digital tablet displaying floating DNA double helix graphics, representing genetic research or medical technology.

    A recent case report describes an extremely rare solitary fibrous tumor (SFT) occurring in the maxilla (upper jaw), highlighting the importance of accurate diagnosis in rare soft tissue tumors.

    Although SFT is different from synovial sarcoma, both are rare mesenchymal tumors that can present similarly, making diagnosis dependent on specialized testing.

    A Rare Presentation

    A 31-year-old patient developed a slow-growing, painless mass in the upper jaw. Imaging revealed a tumor involving the maxillary bone.

    Diagnosis required:

    • Imaging (CT and MRI)
    • Histopathology
    • Immunohistochemistry

    The tumor was confirmed through STAT6 positivity, a defining biomarker of SFT.

    Why Accurate Diagnosis Matters

    Rare tumors like SFT and synovial sarcoma can resemble other spindle cell tumors, making precise diagnosis critical.

    Synovial sarcoma is typically identified through:

    • SS18-SSX gene fusion
    • Immunohistochemistry
    • Expert pathology review

    This case reinforces the growing role of molecular and biomarker testing in distinguishing rare cancers and guiding care.

    Treatment and Follow-Up

    The tumor was successfully treated with complete surgical resection, the standard approach for localized soft tissue tumors.

    However, long-term follow-up is essential, as some tumors may recur over time — a challenge also seen in synovial sarcoma.

    What This Means for the Synovial Sarcoma Community

    This case reflects broader themes in synovial sarcoma care:

    • Rare and unexpected tumor presentations
    • Need for specialized sarcoma expertise
    • Importance of biomarker-driven diagnosis
    • Ongoing monitoring after treatment

    Ask About Biomarker Testing — It Opens Doors to Targeted Care

    Biomarker testing can help guide treatment decisions and expand options.

    It may open access to:

    • Targeted therapies and cell therapies like Tecelra
    • Clinical trials
    • Emerging treatments such as lete-cel

    Start the Conversation

    Ask your care team if these tests have been completed:

    • HLA typing
    • MAGE-A4 testing
    • NY-ESO-1 testing

    If not, you can request them. Labs like Caris Life Sciences and Tempus specialize in sarcoma profiling.

    Biomarker testing is a key step in understanding your full range of options.

    For resources, visit: www.sarcomabiomarkertesting.com

    For more detailed information, please refer to the original publication. For more information about synovial sarcoma resources and support, please visit our website.

    • biomarker testing synovial sarcoma
    • soft tissue sarcoma testing
    • solitary fibrous tumor
    • STAT6 marker SFT
    • Synovial Sarcoma Foundation
    ayushis

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (4)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (26)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma
    • Webinar recording poster titled “Inside the Synovial Sarcoma Foundation” featuring speakers Nathan Imperiale and Philip Leider, recorded October 9, 2026, and sponsored by US WorldMeds.
      Two Leaders, One Mission: Nathan Imperiale and Philip Leider on Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CellTherapy #ClinicalTrials #KnowYourOptions #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SarcomaCommunity #SoftTissueSarcoma #SynovialSarcoma #SynovialSarcomaFoundation Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma solitary fibrous tumor Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma case report synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma misdiagnosis synovial sarcoma research synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA Tecelra synovial sarcoma webinar

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch